dismiss

Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

MRI Homepage

Siemens focuses on digitalization at HIMSS Its expanded digital service portfolio will be on display

Prestige Medical Imaging partners with Esaote and Glassbeam Expands portfolio to include MR, ultrasound and analytical software

First 7T whole-body MR scanner in Canada installed in Montreal Produces high-resolution images at pixel dimensions measured in tenths of a millimeter

Fujifilm to unveil latest version of Synapse 3D platform at HIMSS Five new capabilities for advanced visualization

Medic Vision to deploy iQMR in China through new partnership with KAME Address extreme overload of imaging requests in China

Philips and MIM Software collab to streamline radiotherapy treatment planning Integrate portfolios of CT, MR and software solutions

Dennis Durmis MITA names chair of board of directors

Ohio State to treat epilepsy patients with focused ultrasound in world's first clinical trial For when seizures can't be controlled with medication

FDA gives nod to Siemens' MAGNETOM Lumina 3T MR Cost efficient alternative to MAGNETOM Vida MR system

IRADIMED halts Europe-bound deliveries of MR vital sign monitor CE Mark expiring this month

A new technique picks up relevantly
clinical tumors not detected by
ultrasound in prostate cancer scans

Surgeons should rely on visual interpretations and software for tumor detection, says study

John R. Fischer , Staff Reporter
Researchers at University College London are recommending surgeons rely on both their visual interpretations and a software product used to identify clinically relevant prostate tumors not picked up by conventional ultrasound for biopsy guidance, based on the findings of a new study.

Deployed through a system called SmartTarget, the program enhances the technique of MR-targeted biopsies by relaying tumor information collected from the scans onto ultrasound images to identify malignancies and guide surgeons in removing them during biopsy procedures.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



"The software provides them with a clear target," Dr. Dean Barratt, professor of medical physics and biomedical engineering at the UCL Centre for Medical Image Computing, and the inventor of the SmartTarget system, said in a statement. "As MR-targeted biopsies require a very high degree of expertise and experience, we hope that the imagery displayed by SmartTarget will help to bring high accuracy prostate cancer diagnosis to a much wider range of patients and hospitals."

The use of MR scans in detecting the location of tumors prior to biopsies has boosted detection rates from 50 to 90 percent in the last five years.

The SmartTarget system leverages the approach by utilizing advanced image processing and machine learning to create a 3D model of the prostate and cancer from the MR scan of a patient, and then fuses it with ultrasound images during a biopsy. The combination highlights the area of concern, which otherwise would not appear in the ultrasound images.

Researchers applied the technology to 129 patients with suspected prostate cancer. Each underwent a biopsy that utilized SmartTarget and another in which the surgeon visually reviewed the scan, with each detecting 93 clinically significant prostate cancers and identifying up to 80 of the malignancies. Each approach missed 13 that were picked up by the other.

Based on their findings, the developers of the system recommend using it in conjunction with visual interpretations, predicting both together reducing the number of biopsies required, as well as unnecessary surgeries caused by over-diagnosis of less harmful cancers.

"With this study we now have hard data showing that SmartTarget is as good as a group of experts in targeting tumours in the prostate, and have a glimpse of how clinicians and computers will be working together in the future for the good of the patient," said co-senior author, Professor Mark Emberton, dean of UCL Medical Sciences, in a statement.

The SmartTarget software has been commercialized by SmartTarget, a company spun off of UCL's commercialization company, UCL Business PLC, and is in use at hospitals throughout the U.S. and the U.K.

The study was funded by the U.K. Department of Health and Social Care and Wellcome Health Innovation Challenge Funding.

The findings were published in the journal, European Urology.

MRI Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2019 DOTmed.com, Inc.
版权所有